Top of this page
Skip navigation, go straight to the content Newsroom UCB U.S. News


Press Release: UCB to provide additional information to the U.S. FDA regarding midazolam nasal spray submission

  • UCB_LOGO_1280x960

    Brussels (Belgium) & Atlanta, Georgia (U.S.) - April 1, 2019:
    UCB announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for acute repetitive seizures (ARS, also known as seizure clusters) in patients with epilepsy. UCB acquired the rights to midazolam nasal spray from Proximagen in June 2018.

    The FDA request for additional information is not related to the safety or efficacy data submitted to support the application. As UCB will hold the NDA, the FDA is requiring an update to the New Drug Application to include information related to UCB’s quality systems related specifically to the regulations governing devices.  
    UCB will work with FDA to determine next steps and will make sure to provide them with the specific information they need. We look forward to being able to bring this important medicine to patients.

    At UCB, we remain committed to delivering value to patients with unmet needs, including those living with uncontrolled seizures.

    For further information, UCB:

    US Communications
    Allyson Funk, Head of U.S. Communications, UCB
    T +1.678.365.6321,

    Corporate Communications

    France Nivelle, Global Communications, UCB
    T +32.2.559.9178,

    Laurent Schots, Media Relations, UCB
    T +32.2.559.92.64,
    Investor Relations
    Antje Witte, Investor Relations, UCB
    T +32.2.559.94.14,

    Isabelle Ghellynck, Investor Relations, UCB

    Brand Communications

    Jim Baxter, Neurology Communications, UCB

    About UCB
    UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA


  • Like